Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
Clinical trial NCT03062358 · COMPLETED
Trial details
- NCT number
- NCT03062358
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-27
- Primary completion
- 2021-06-30
- Enrollment
- 453
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.